Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Oncosec Medical (ONCS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
OncoSec Reports Updated Tumor Responses in KEYNOTE-695 Study of TAVO(TM) + KEYTRUDA® in Refractory Metastatic Melanoma

OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing novel cancer immunotherapies, today announced an update regarding tumor responses in its KEYNOTE-695 global, multicenter Phase...

ONCS : 0.77 (-2.77%)
OncoSec Presents New Data Showing A Single Cycle Of Monotherapy TAVO(TM) Can Generate Productive Immune Responses In Triple Negative Breast Cancers (TNBC)

OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, announced today the presentation of new data that suggests treatment with TAVO(TM) (tavokinogene...

ONCS : 0.77 (-2.77%)
OncoSec Receives $7 Million Investment From Alpha Holdings At $1.50 Per Share

OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing intratumoral cancer immunotherapies, announced today that the Company has received a $7.0 million investment at $1.50 per share...

ONCS : 0.77 (-2.77%)
OncoSec Presents New Data During Oral Presentation At Melanoma Bridge Demonstrating Intratumoral Monotherapy TAVO(TM) Induces Abscopal Responses In Metastatic Melanoma Patients

OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing intratumoral cancer immunotherapies, announced today the presentation of new data from the company's Phase 2 study of TAVO(TM)...

ONCS : 0.77 (-2.77%)
OncoSec To Present Data in Late-Stage Triple Negative Breast Cancer (TNBC) at the 2018 San Antonio Breast Cancer Symposium®

OncoSec Medical Inc., (OncoSec) (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, today announced that TAVO(TM) will be featured in two poster sessions during the 2018 San Antonio...

ONCS : 0.77 (-2.77%)
Today's Research Reports on Stocks to Watch: Vericel and OncoSec Medical

NEW YORK, NY / ACCESSWIRE / November 7, 2018 / Vericel Corporation, a commercial-stage biopharmaceutical company, that researches, develops, manufactures, markets, and sells patient-specific expanded cellular...

ONCS : 0.77 (-2.77%)
VCEL : 17.10 (unch)
OncoSec Doses First Patient in KEYNOTE-890 Phase 2 Clinical Trial

OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, today announced that the first patient has been treated in KEYNOTE-890, a Phase 2 clinical...

ONCS : 0.77 (-2.77%)
OncoSec Announces Preliminary Data from KEYNOTE-695 Study Accepted for Late-Breaking Presentation at SITC Annual Meeting

OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, today announced that preliminary clinical and immunological data from its ongoing KEYNOTE-695...

ONCS : 0.77 (-2.77%)
OncoSec Appoints Kellie Malloy Foerter as Chief Clinical Development Officer

OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, today announced the appointment of Kellie Malloy Foerter to the position of Chief Clinical...

ONCS : 0.77 (-2.77%)
OncoSec Announces Publication of Data in Nature Gene Therapy Demonstrating the Ability of its Newly Optimized Intratumoral IL-12 Immunotherapy Platform to Increase Systemic Anti-tumor Responses in both Treated and Untreated Lesions

OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, today announced the publication of a study in the peer-reviewed journal, Nature Gene Therapy...

ONCS : 0.77 (-2.77%)
OncoSec Initiates KEYNOTE-890, a Phase 2 Clinical Trial of TAVO in Combination with Merck's KEYTRUDA® (pembrolizumab) for the Treatment of Late-Stage Triple Negative Breast Cancer

OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, today announced that it has initiated KEYNOTE-890, a Phase 2 clinical trial for the treatment...

ONCS : 0.77 (-2.77%)
OncoSec Announces Closing of First Tranche of $15 Million At Market Investment from Alpha Holdings, Inc.

OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing intratumoral cancer immunotherapies, today announced the closing of the first $8 million tranche of its $15 million investment...

ONCS : 0.77 (-2.77%)
OncoSec Chief Scientific Officer to Present at Advances in Immuno-Oncology USA Congress

OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, today announced that its Chief Scientific Officer Christopher G. Twitty, PhD, will give a...

ONCS : 0.77 (-2.77%)
Data from OncoSec's OMS-100 Clinical Trial Accepted for Oral Presentation at the 2018 Melanoma Bridge Conference

OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, today announced that Dr. Alain Algazi, Associate Professor of Medicine at UCSF, will present...

ONCS : 0.77 (-2.77%)
OncoSec to Present at Cantor Fitzgerald Global Healthcare Conference

OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing intratumoral cancer immunotherapies, today announced that Daniel J. O'Connor, President and Chief Executive Officer of OncoSec,...

ONCS : 0.77 (-2.77%)
OncoSec Announces $15 Million At Market Investment from Alpha Holdings, Inc.

OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing intratumoral cancer immunotherapies, today announced that it has secured a $15 million investment from Alpha Holdings, Inc. (KOSDAQ:...

ONCS : 0.77 (-2.77%)
OncoSec Expands Relationship with Merck, Announces Clinical Collaboration to Evaluate Combination of ImmunoPulse® IL-12 and KEYTRUDA® (pembrolizumab) for Triple Negative Breast Cancer

OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, has entered a clinical trial collaboration and supply agreement with Merck (known as MSD...

ONCS : 0.77 (-2.77%)
Free Research Reports on These Biotech Stocks -- MannKind, Marinus Pharma, Mirati Therapeutics, and OncoSec Medical

If you want a free Stock Review on MNKD, MRNS, MRTX, and ONCS sign up now at www.wallstequities.com/registration. WallStEquities.com has initiated research coverage on MannKind Corp. (NASDAQ: MNKD), Marinus...

ONCS : 0.77 (-2.77%)
MRTX : 40.38 (-2.68%)
MNKD : 1.68 (-1.75%)
MRNS : 3.62 (-2.43%)
OncoSec to Present at Eighth Annual BioNJ BioPartnering Conference

OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, today announced that Daniel J. O'Connor, Chief Executive Officer of OncoSec, will present...

ONCS : 0.77 (-2.77%)
OncoSec Announces PISCES/KEYNOTE-695 Trial-in-Progress Poster Presentation at Upcoming ASCO 2018 Annual Meeting

OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing intratumoral cancer immunotherapies, will present a trial-in-progress poster presentation from its global, multi-center, registration-directed...

ONCS : 0.77 (-2.77%)

Van Meerten Stock Picks

Tesla According to Peter Lynch
Today's Barchart Chart of the Day will be the auto maker Tesla (TSLA).
TSLA -11.08
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.
Free Commodities Newsletter

Get prepared for your trading day with

Barchart's Commodity Futures Morning Update Email

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

cmdty Insider - Ag Market Commentary

Today's Commentary

Corn futures ended the Friday session with most contracts steady to 1/2 cent higher, as Dec expired at $3.76 3/4. USDA reported a private export sale of 125,000 MT of corn to Japan this morning. Corn export commitments through December 6 were 16.3% l...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar